Bridgeway Capital Management, LLC Corvus Pharmaceuticals, Inc. Transaction History

Bridgeway Capital Management, LLC

$3.75 Billion
Q1 2025

A detailed history of Bridgeway Capital Management, LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 41,300 shares of CRVS stock, worth $185,850. This represents 0.0% of its overall portfolio holdings.

Number of Shares

41,300

Previous 41,300 -0.0%

Holding current value

$185,850

Previous $214,000 38.79%

% of portfolio

0.0%

Previous 0.01%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$4.55 - $9.56 $391,300 - $822,160	-86,000 Reduced 67.56%	41,300 $214,000
Q2 2024 Aug 14, 2024	SELL	$1.36 - $2.29 $131,920 - $222,130	-97,000 Reduced 43.25%	127,300 $231,000
Q1 2024 May 15, 2024	BUY	$1.76 - $2.41 $132,000 - $180,750	75,000 Added 50.23%	224,300 $399,000
Q3 2023 Nov 14, 2023	BUY	$1.41 - $2.97 $56,400 - $118,800	40,000 Added 36.6%	149,300 $217,000
Q2 2023 Aug 14, 2023	SELL	$1.0 - $3.86 $50,000 - $193,000	-50,000 Reduced 31.39%	109,300 $250,000
Q1 2022 May 16, 2022	SELL	$1.46 - $2.48 $94,900 - $161,200	-65,000 Reduced 28.98%	159,300 $261,000
Q4 2021 Feb 14, 2022	BUY	$2.34 - $5.31 $152,100 - $345,150	65,000 Added 40.8%	224,300 $541,000
Q3 2021 Nov 15, 2021	SELL	$1.89 - $8.53 $94,500 - $426,499	-50,000 Reduced 23.89%	159,300 $771,000
Q2 2021 Aug 16, 2021	BUY	$2.46 - $3.14 $12,300 - $15,700	5,000 Added 2.45%	209,300 $559,000
Q1 2021 May 17, 2021	BUY	$2.86 - $4.77 $201,916 - $336,761	70,600 Added 52.8%	204,300 $629,000
Q4 2019 Feb 14, 2020	BUY	$2.56 - $5.44 $342,272 - $727,328	133,700 New	133,700 $727,000
Q2 2019 Aug 14, 2019	SELL	$3.3 - $4.58 $293,700 - $407,620	-89,000 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$3.75 - $4.97 $35,250 - $46,718	9,400 Added 11.81%	89,000 $358,000
Q4 2018 Feb 14, 2019	SELL	$3.29 - $8.94 $82,250 - $223,500	-25,000 Reduced 23.9%	79,600 $292,000
Q3 2018 Nov 13, 2018	BUY	$8.58 - $11.4 $168,168 - $223,440	19,600 Added 23.06%	104,600 $897,000
Q3 2017 Nov 14, 2017	BUY	$11.3 - $17.23 $960,500 - $1.46 Million	85,000	85,000 $1.36 Million

Others Institutions Holding CRVS

# of Institutions

113

Shares Held

39.9M

Call Options Held

1.37M

Put Options Held

338K

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $209M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.

Account

Bridgeway Capital Management, LLC Corvus Pharmaceuticals, Inc. Transaction History